172 related articles for article (PubMed ID: 23541530)
1. The unusual mechanism of inhibition of the p90 ribosomal S6 kinase (RSK) by flavonol rhamnosides.
Utepbergenov D; Derewenda ZS
Biochim Biophys Acta; 2013 Jul; 1834(7):1285-91. PubMed ID: 23541530
[TBL] [Abstract][Full Text] [Related]
2. Three acetylated flavonol glycosides from Forsteronia refracta that specifically inhibit p90 RSK.
Xu YM; Smith JA; Lannigan DA; Hecht SM
Bioorg Med Chem; 2006 Jun; 14(11):3974-7. PubMed ID: 16524738
[TBL] [Abstract][Full Text] [Related]
3. Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.
Utepbergenov D; Derewenda U; Olekhnovich N; Szukalska G; Banerjee B; Hilinski MK; Lannigan DA; Stukenberg PT; Derewenda ZS
Biochemistry; 2012 Aug; 51(33):6499-510. PubMed ID: 22846040
[TBL] [Abstract][Full Text] [Related]
4. Identification of quercitrin as an inhibitor of the p90 S6 ribosomal kinase (RSK): structure of its complex with the N-terminal domain of RSK2 at 1.8 Å resolution.
Derewenda U; Artamonov M; Szukalska G; Utepbergenov D; Olekhnovich N; Parikh HI; Kellogg GE; Somlyo AV; Derewenda ZS
Acta Crystallogr D Biol Crystallogr; 2013 Feb; 69(Pt 2):266-75. PubMed ID: 23385462
[TBL] [Abstract][Full Text] [Related]
5. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers.
Aronchik I; Appleton BA; Basham SE; Crawford K; Del Rosario M; Doyle LV; Estacio WF; Lan J; Lindvall MK; Luu CA; Ornelas E; Venetsanakos E; Shafer CM; Jefferson AB
Mol Cancer Res; 2014 May; 12(5):803-12. PubMed ID: 24554780
[TBL] [Abstract][Full Text] [Related]
6. Identifying requirements for RSK2 specific inhibitors.
Wright EB; Fukuda S; Li M; Li Y; O'Doherty GA; Lannigan DA
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1798-1809. PubMed ID: 34348556
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2.
Malakhova M; Tereshko V; Lee SY; Yao K; Cho YY; Bode A; Dong Z
Nat Struct Mol Biol; 2008 Jan; 15(1):112-3. PubMed ID: 18084304
[TBL] [Abstract][Full Text] [Related]
8. Identification of inhibitors against p90 ribosomal S6 kinase 2 (RSK2) through structure-based virtual screening with the inhibitor-constrained refined homology model.
Li S; Zhou Y; Lu W; Zhong Y; Song W; Liu K; Huang J; Zhao Z; Xu Y; Liu X; Li H
J Chem Inf Model; 2011 Nov; 51(11):2939-47. PubMed ID: 21995341
[TBL] [Abstract][Full Text] [Related]
9. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.
Smith JA; Poteet-Smith CE; Xu Y; Errington TM; Hecht SM; Lannigan DA
Cancer Res; 2005 Feb; 65(3):1027-34. PubMed ID: 15705904
[TBL] [Abstract][Full Text] [Related]
10. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.
Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B
Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756
[TBL] [Abstract][Full Text] [Related]
11. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
12. The p90 ribosomal S6 kinase (RSK) is a mediator of smooth muscle contractility.
Artamonov M; Momotani K; Utepbergenov D; Franke A; Khromov A; Derewenda ZS; Somlyo AV
PLoS One; 2013; 8(3):e58703. PubMed ID: 23516539
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of a potent and selective inhibitor of p90 Rsk.
Maloney DJ; Hecht SM
Org Lett; 2005 Mar; 7(6):1097-9. PubMed ID: 15760148
[TBL] [Abstract][Full Text] [Related]
14. Structural diversity of the active N-terminal kinase domain of p90 ribosomal S6 kinase 2.
Malakhova M; Kurinov I; Liu K; Zheng D; D'Angelo I; Shim JH; Steinman V; Bode AM; Dong Z
PLoS One; 2009 Nov; 4(11):e8044. PubMed ID: 19956600
[TBL] [Abstract][Full Text] [Related]
15. Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study.
Casalvieri KA; Matheson CJ; Backos DS; Reigan P
Bioorg Med Chem; 2020 Mar; 28(5):115303. PubMed ID: 31982240
[TBL] [Abstract][Full Text] [Related]
16. Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases.
Andersen JL; Gesser B; Funder ED; Nielsen CJF; Gotfred-Rasmussen H; Rasmussen MK; Toth R; Gothelf KV; Arthur JSC; Iversen L; Nissen P
Nat Commun; 2018 Oct; 9(1):4344. PubMed ID: 30341347
[TBL] [Abstract][Full Text] [Related]
17. Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis.
Zhong Y; Xue M; Zhao X; Yuan J; Liu X; Huang J; Zhao Z; Li H; Xu Y
Bioorg Med Chem; 2013 Apr; 21(7):1724-34. PubMed ID: 23434140
[TBL] [Abstract][Full Text] [Related]
18. Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/Thr kinase, RSK.
Smith JA; Maloney DJ; Clark DE; Xu Y; Hecht SM; Lannigan DA
Bioorg Med Chem; 2006 Sep; 14(17):6034-42. PubMed ID: 16723233
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the activity of the RSK-specific inhibitor, SL0101.
Smith JA; Maloney DJ; Hecht SM; Lannigan DA
Bioorg Med Chem; 2007 Jul; 15(14):5018-34. PubMed ID: 17512736
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Potent and Selective RSK Inhibitors as Biological Probes.
Jain R; Mathur M; Lan J; Costales A; Atallah G; Ramurthy S; Subramanian S; Setti L; Feucht P; Warne B; Doyle L; Basham S; Jefferson AB; Lindvall M; Appleton BA; Shafer CM
J Med Chem; 2015 Sep; 58(17):6766-83. PubMed ID: 26270416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
